Peter Riedell, MD, of the University of Chicago Medicine, discussed his research on liso-cel for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) at the 65th American Society of Hematology Annual Meeting & Exposition.

Dr. Riedell and colleagues conducted a real-world analysis of 101 patients who received liso-cel in the standard-of-care setting. A total of 35% of patients were older than 75 years and had received a median of three prior lines of therapy, and 68% of patients had a Charlson Comorbidity Index score of three or greater.

Dr. Riedell highlighted two major findings from the study. First, polatuzumab-based bridging was associated with high overall and complete response rates, and those who responded to bridging therapy (eg, achieved a partial or complete response) had superior progression-free survival compared with patients who had stable or progressive disease.

Secondly, researchers were able to look at the activity of liso-cel in patients with secondary central nervous system (CNS) involvement, and they found that eight of 11 patients with CNS involvement achieved complete remission.

“I think the results that we presented compare favorably [with] those noted in the pivotal clinical trials,” Dr. Riedell said. “That's a reflection of our use of bridging therapy, patient selection, and toxicity management.”

Moving forward, Dr. Riedell and colleagues are looking to compare the results of this modern cohort with patients treated with other products, such as axi-cel, to better understand patient selection and toxicity management.

свернуть